Bankruptcy Bid: XNK Therapeutics

XNK Therapeutics AB was declared bankrupt on April 9, 2024. The Södertörns District Court appointed Anders Svensson Clark as bankruptcy trustee.

XNK Therapeutics is a clinical-stage biotechnology company developing unique and individualized natural killer cell-based cancer therapies.

If you wish to submit a bid on the company’s business and/or assets, please contact anders.svensson.clark@se.dlapiper.com and therese.isaksson@se.dlapiper.com.

Update 1

On 6 May 2024, the bankruptcy estate sold the GMP facility referred to in the information memorandum together with the assets located in the GMP facility and transferred the lease agreement for the GMP facility to the new tenant. The bankruptcy estate is now seeking to sell the patents and the intellectual property (IP) developed by XNK Therapeutics AB.

Update 2

In the end of May 2024, the bankruptcy estate sold the IP developed by XNK Therapeutics AB.

Update 3

On 25 February 2025, the bankruptcy trustee submitted a dividend proposal entailing a recovery rate of 29 percent with respect to unsecured creditors. The high recovery rate is a result of the successful sales summarized in Update 1 and Update 2 (no distributions would have been feasible without the asset and IP transfer). The dividend proposal is based on the order of priority under Swedish law. For the avoidance of doubt, no distributions will be made to the shareholders. We are now awaiting court approval of the dividend proposal and the bankruptcy proceeding will then be completed.